Wells Fargo & Company Syros Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.69 - $1.21 $4,319 - $7,574	-6,260 Reduced 94.55%	361 $0
Q1 2022 May 16, 2022	SELL	$1.02 - $3.8 $20,795 - $77,474	-20,388 Reduced 75.49%	6,621 $8,000
Q4 2021 Feb 14, 2022	BUY	$3.26 - $4.66 $87,570 - $125,176	26,862 Added 18273.47%	27,009 $88,000
Q2 2021 Aug 16, 2021	SELL	$5.01 - $7.48 $44,158 - $65,928	-8,814 Reduced 98.36%	147 $1,000
Q1 2021 May 13, 2021	SELL	$7.19 - $14.95 $483,534 - $1.01 Million	-67,251 Reduced 88.24%	8,961 $67,000
Q4 2020 Feb 09, 2021	SELL	$6.66 - $14.66 $37,602 - $82,770	-5,646 Reduced 6.9%	76,212 $827,000
Q3 2020 Nov 05, 2020	SELL	$8.69 - $14.47 $10,836 - $18,044	-1,247 Reduced 1.5%	81,858 $724,000
Q2 2020 Aug 13, 2020	BUY	$5.21 - $11.03 $314,355 - $665,517	60,337 Added 265.01%	83,105 $886,000
Q1 2020 May 14, 2020	BUY	$4.46 - $9.2 $101,545 - $209,465	22,768 New	22,768 $135,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.